UMC is looking for a new director to lead an organisation of over 100 people in Uppsala, Sweden, devoted to supporting and enhancing global pharmacovigilance and patient safety.
Uppsala Monitoring Centre (UMC) is a non-profit foundation and centre for medicine safety and scientific research. Our vision is a world where all patients and health professionals make wise therapeutic decisions in their use of medicines. Our mission is to support and promote patient safety through effective global pharmacovigilance practice. UMC explores the benefits and risks of medicines to help minimise harm to patients, and offers products and services used by health authorities and the pharmaceutical industry. For more than 40 years, UMC has provided scientific leadership and operational support to the WHO Programme for International Drug Monitoring.
As the director you will report to a board consisting of members appointed by the Swedish government and the World Health Organization. You will be responsible for the scientific and business operations of the centre, matters relating to the WHO Programme for International Drug Monitoring, and relationships with other organisations. You will develop strategy, lead the team in Uppsala and represent UMC worldwide. All this in close collaboration with colleagues in Geneva and other global partners.
You will need the following qualities and characteristics:
Highly desirable qualities:
We are looking for a medical expert or scientist with suitable experience. Fluent English is a prerequisite and a good knowledge of other languages would be an advantage. This is a full-time post based in Uppsala, Sweden. UMC offers a competitive remuneration package with pension within the confines of the Swedish framework.
For any additional questions, please contact Dr Anders Milton +46(0)73-091 03 32.
If you feel you are the right candidate for this role, please send your CV and covering letter to firstname.lastname@example.org with the subject line UMC Director. The closing date for applications is Monday 13 April 2020.